For research use only. Not for therapeutic Use.
CHPG sodium salt is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells[1]. CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways.[2].
CHPG sodium salt (10-500 µM; 24 hours) significantly increases the cell viability and decreases the LDH release after SO2 derivatives treatment[1].
CHPG sodium salt (0.5 mM; 30 mins ) protects BV2 cells against SO2-induced apoptosis[1].
CHPG sodium salt (0.5 mM; 30 mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels[1].
CHPG sodium salt (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume[2].
Catalog Number | I010811 |
CAS Number | 1303993-73-8 |
Synonyms | sodium;2-amino-2-(2-chloro-5-hydroxyphenyl)acetate |
Molecular Formula | C8H7ClNNaO3 |
Purity | ≥95% |
InChI | InChI=1S/C8H8ClNO3.Na/c9-6-2-1-4(11)3-5(6)7(10)8(12)13;/h1-3,7,11H,10H2,(H,12,13);/q;+1/p-1 |
InChIKey | KZRZZIISUUINJT-UHFFFAOYSA-M |
SMILES | C1=CC(=C(C=C1O)C(C(=O)[O-])N)Cl.[Na+] |
Reference | [1]. Qiu JL, et al. The selective mGluR5 agonist CHPG attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. Neurochem Int. 2015 Jun-Jul;85-86:46-52. [2]. Chen T, et al. The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway. Int J Mol Med. 2012 Apr;29(4):630-6. |